GlaxoSmithKline won a further 22 orders for its H1N1 swine flu vaccine in the last two months, taking the total number of doses ordered to some $3.5 billion
A dearth of new products, new technologies and fresh commitments by governments have lured US drugmakers back into the flu vaccine business
Tiny companies with big ideas for making flu vaccines have captured the attention of investors and governments looking for a quicker way to make a vaccine
